Pharmaceutical Executive May 13, 2022
Dharmendra Sahay, Vijesh Unnikrishnan

Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.

For over a decade, the pharmaceutical and biotech industry has invested steadily in digital and connected health capabilities aimed at improving outcomes with patient-centric solutions.1 But progress has been slow, and confidence in the impact of digital health initiatives has dwindled. In a recent ZS survey, fewer than half of pharma executives reported generating value from their investments in digital initiatives broadly, including patient digital efforts.

While pharma contemplates its role in the future of digital health, other players are doubling down. New digitally native entrants are reframing the definition of outcomes more holistically in behavioral, functional, and clinical spheres that span therapy areas...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Technology
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
Pharmacies Should Adopt Proactive Health, Wellness to Help Patients
Advancing Healthcare Solutions: Harnessing Collaborative Business Models for Oncology
AI Identifies New Potential Treatments For Parkinson’s Disease

Share This Article